| Literature DB >> 28877186 |
Gabriele Papini1,2,3, Alberto G Bonomi3, Wim Stut3, Jos J Kraal4,5, Hareld M C Kemps5, Francesco Sartor3.
Abstract
Cardiorespiratory fitness (CRF) provides important diagnostic and prognostic information. It is measured directly via laboratory maximal testing or indirectly via submaximal protocols making use of predictor parameters such as submaximal [Formula: see text], heart rate, workload, and perceived exertion. We have established an innovative methodology, which can provide CRF prediction based only on body motion during a periodic movement. Thirty healthy subjects (40% females, 31.3 ± 7.8 yrs, 25.1 ± 3.2 BMI) and eighteen male coronary artery disease (CAD) (56.6 ± 7.4 yrs, 28.7 ± 4.0 BMI) patients performed a [Formula: see text] test on a cycle ergometer as well as a 45 second squatting protocol at a fixed tempo (80 bpm). A tri-axial accelerometer was used to monitor movements during the squat exercise test. Three regression models were developed to predict CRF based on subject characteristics and a new accelerometer-derived feature describing motion decay. For each model, the Pearson correlation coefficient and the root mean squared error percentage were calculated using the leave-one-subject-out cross-validation method (rcv, RMSEcv). The model built with all healthy individuals' data showed an rcv = 0.68 and an RMSEcv = 16.7%. The CRF prediction improved when only healthy individuals with normal to lower fitness (CRF<40 ml/min/kg) were included, showing an rcv = 0.91 and RMSEcv = 8.7%. Finally, our accelerometry-based CRF prediction CAD patients, the majority of whom taking β-blockers, still showed high accuracy (rcv = 0.91; RMSEcv = 9.6%). In conclusion, motion decay and subject characteristics could be used to predict CRF in healthy people as well as in CAD patients taking β-blockers, accurately. This method could represent a valid alternative for patients taking β-blockers, but needs to be further validated in a larger population.Entities:
Mesh:
Year: 2017 PMID: 28877186 PMCID: PMC5587281 DOI: 10.1371/journal.pone.0183740
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Subjects’ characteristics.
| n | Weight [kg] | Height [cm] | BMI [kg/m2] | Age [years] | RFSmax | |
|---|---|---|---|---|---|---|
| 12 | 67.9±8.2 | 170.1±4.8 | 23.4±2.4 | 31.3±8.4 | 16.2±5.9 | |
| 18 | 83.7±9.8 | 178.9±5.9 | 26.2±3.2 | 31.2±7.7 | 20.2±8.5 | |
| 30 | 77.4±12 | 175.4±7.0 | 25.1±3.2 | 31.3±7.8 | 18.6±7.7 | |
| 18 | 93.7±11.7 | 180.8±6.6 | 28.7±4 | 56.6±7.4 | 4.6±1.8 |
RFSmax = Maximum cross-correlation between the initial and last parts of the accelerometer signal (explained in detail in the Data Analysis section).
*,*** = significant difference between the two sexes in the healthy group, p<0.05, and p<0.001, respectively.
+,++,+++ = significant difference between the healthy group and the CAD patients group; p<0.05, p<0.01 and p<0.001, respectively.
§,§§,§§§ = significant difference between the male subjects in the healthy group and in the CAD patients group, p<0.05, p<0.01 and p<0.001, respectively.
Coronary artery disease patients.
| Subject | Diagnose | Intervention | β-blocker | dose [mg] | ACE inhibitor | dose [mg] | AR blocker | dose [mg] |
|---|---|---|---|---|---|---|---|---|
| 1 | non STEMI | PCI | Metoprolol | 50 | Perindopril | 4 | ||
| 2 | suspected AP | Drug treatment | Metoprolol | 50 | Lisinopril | 5 | ||
| 3 | non STEMI | PCI | Metoprolol | 50 | Perindopril | 4 | ||
| 4 | stable AP | CABG | Metoprolol | 50 | ||||
| 5 | MI | PCI (DES) | Metoprolol | 50 | Perindopril | 2 | ||
| 6 | non STEMI | PCI | ||||||
| 7 | non STEMI | Drug treatment | Metoprolol | 100 | Perindopril | 2 | ||
| 8 | AP | PCI | Metoprolol | 100 | ||||
| 9 | non STEMI | Drug treatment | ||||||
| 10 | non STEMI | Drug treatment | Metoprolol | 50 | Perindopril | 4 | ||
| 11 | MI | PCI | Metoprolol | 100 | Valsartan | 160 | ||
| 12 | MI | Drug treatment | Metoprolol | 50 | Lisinopril | 5 | ||
| 13 | AP | PCI | Metoprolol | 50 | ||||
| 14 | non STEMI | CABG | Metoprolol | 100 | ||||
| 15 | MI | PCI | Metoprolol | 50 | Enalapril | 5 | ||
| 16 | non STEMI | PCI | Metoprolol | 100 | Perindopril | 2 | ||
| 17 | complains of AP | Drug treatment | Valsartan | 320 | ||||
| 18 | AP | CABG | Metoprolol | 100 |
STEMI = ST elevated myocardial infarction; AP = angina pectoris, PCI = percutaneous coronary intervention, CABG = coronary artery bypass graft, DES = drug-eluting stent
* Both patients #2 and #17 had documented coronary artery disease. Patient #2 had a PCI and patient #17 had a CABG intervention in their recent history. However, both patients returned to the hospital with suspected AP. Drug treatment was intensified and they were referred to cardiac rehabilitation.
Fig 1Study workflow and accelerometer output comparison.
A) Flowchart describing the main elements of the study B) Examples of 5 seconds segments of the magnitude at the beginning and at the end of the squat exercise in an unfit and a fit representative subject.
Multiple linear regression models to predict .
| Coef. | SE | t | r | Adj.r2 | RMSE | Bias | LoA | (LOOCV) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| (L·min-1) | (L·min-1) | (L·min-1) | (L·min-1) | |||||||
| 0.786 | 0.556 | 0.437 | 0.001 | 0.962 | 0.482 | |||||
| -0.956 | ||||||||||
| Constant | 1.58700 | 0.725 | 2.191 | 0.038 | ||||||
| Body Weight | 0.01443 | 0.009 | 1.492 | 0.148 | ||||||
| Age | -0.01759 | 0.011 | -1.616 | 0.119 | ||||||
| Sex | 0.67400 | 0.238 | 2.834 | 0.009 | ||||||
| RFsmax | 0.01712 | 0.012 | 1.479 | 0.152 | ||||||
| 0.955 | 0.882 | 0.183 | 0.009 | 0.456 | 0.221 | |||||
| -0.437 | ||||||||||
| Constant | 0.14500 | 0.581 | 0.249 | 0.808 | ||||||
| Body Weight | 0.02990 | 0.007 | 4.352 | <0.001 | ||||||
| Age | -0.01820 | 0.006 | -3.157 | 0.008 | ||||||
| Sex | 0.18000 | 0.169 | 1.066 | 0.307 | ||||||
| RFsmax | 0.03050 | 0.008 | 3.641 | 0.003 | ||||||
| 0.914 | 0.800 | 0.205 | 0.005 | 0.501 | 0.246 | |||||
| -0.492 | ||||||||||
| Constant | 4.62400 | 0.602 | 7.679 | <0.001 | ||||||
| Body Weight | 0.00311 | 0.005 | 0.672 | 0.512 | ||||||
| Age | -0.05160 | 0.007 | -7.381 | <0.001 | ||||||
| RFsmax | 0.12300 | 0.029 | 4.166 | <0.001 | ||||||
SE = Standard error, RMSE = root mean square error, LoA = limits of agreement, LOOCV = leave one out cross validation root mean square error
Fig 2Bland-Altman plots.
A) Model 1a, healthy subjects; C) Model 1b, normal to low fitness healthy subjects; D) Model 2, CAD patients. Bias and mean values are expressed in L/min.
Fig 3Distribution of the RMSEcv for different fitness categories.
A) Model 1a; B) Model 1b; C) Model 2. The values in each bar represent the RMSEcv in [L/min] and, in parenthesis, the RMSEcv in percentage respect to the average of the fitness category.
Partial correlation between and the different predictors (x = predictor not used).
| Model | N | Weight | Age | Sex | RFSmax |
|---|---|---|---|---|---|
| 30 | 0.29 | -0.31 | 0.49 | 0.28 | |
| 17 | 0.78 | -0.67 | 0.29 | 0.72 | |
| 18 | 0.18 | -0.89 | x | 0.74 |
Partial Correlation expresses the correlation between the dependent variable () and one of the independent variables (Weight, Age, Sex, RFSmax) upon removing the linear effects of the remaining independent variables.